Efficacy and safety of propranolol in the treatment of infantile hemangioma
Objective To study the efficacy and safety of propranolol in the treatment of infantile heman-gioma (IH). Methods A total of fifty children with IH in Xiamen Children's Hospital from January 2021 to De-cember 2023 were selected and divided into a control group and a research group according to different treatment methods,with 25 cases in each group. The control group was treated with lauromacrogol injection,while the re-search group was treated with propranolol hydrochloride tablets,and the therapeutic effect of the two groups was compared. Results The total effective rate of the research group was higher than that of the control group (92％ vs 68％,P<0.05);After 4 weeks and 8 weeks of treatment,the levels of angiogenic factors decreased in both groups,and the levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the re-search group were significantly lower than those in the control group (P<0.05);The incidence of adverse reactions in the research group and control group were 12％ and 20％,respectively,with no statistically significant differ-ence (P>0.05). Conclusion Propranolol can improve the therapeutic effect of IH,improve the levels of angiogenic factors in children,and has high safety,which is worth promoting.
HemangiomaPropranololPolidocanolVascular endothelial growth factorsFibroblast growth factor2Treatment outcomeDrug-related side effeds and adverse reactions
万方数据
维普
